Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01190306 · ClinicalTrials.gov registry record · Phase 3

Safety Study of the VEGA UV-A System to Treat Keratoconus

A Phase 3 study, sponsored by Topcon Medical Systems.

Terminated
Registry status
Phase 3
Development phase
127
Enrollment target

NCT01190306: Clinical Trial Phase 3 study, sponsored by Topcon Medical Systems.

NCT01190306 is a Phase 3 study that was terminated before completion, run by Topcon Medical Systems. The registered enrollment target is 127 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01190306, a Phase 3 study, was terminated before completion, sponsored by Topcon Medical Systems.

TERMINATED
Registry status
Phase 3
Development phase
127 participants
Enrollment target

Study Summary

The purpose of this research study is to test the safety, tolerability, and effectiveness of corneal collagen cross-linking (CXL), when used to treat keratoconus.

Interventions

  • DRUG Riboflavin
  • DEVICE The VEGA UV-A Illumination System

Trial Details

FieldValue
Enrollment Target 127 participants
Start Date 2010-08
Est. Completion 2011-12
Phase Phase 3
Topcon Medical Systems

24 total trials

Why NCT01190306 stopped before completion

NCT01190306 is an interventional study that assigns participants to a tested intervention. The registered 127 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower).

The record links to 0 conditions, and to 2 interventions - of which Riboflavin is the first listed.

NCT01190306 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01190306 about?

NCT01190306 is a clinical study titled "Safety Study of the VEGA UV-A System to Treat Keratoconus". The purpose of this research study is to test the safety, tolerability, and effectiveness of corneal collagen cross-linking (CXL), when used to treat keratoconus.

What is the current status of trial NCT01190306?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 127 participants. The study started on 2010-08. Estimated completion is 2011-12.

What interventions are being tested in trial NCT01190306?

The interventions under investigation include: Riboflavin (DRUG), The VEGA UV-A Illumination System (DEVICE).

Who is sponsoring clinical trial NCT01190306?

This trial is sponsored by Topcon Medical Systems, which has 24 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01190306's enrollment target sits among peer trials

127 1602nd of 2000 higher than 398 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03017820 · 127 participants · Phase 1

    A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

  • NCT03609580 · 127 participants · Phase 1

    Post-operative Urinary Retention (POUR) Following Thoracic Surgery

  • NCT06285643 · 127 participants · Phase 2

    A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

  • NCT06809400 · 127 participants · Phase 1

    A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01190306, the US trial registry maintained by the National Library of Medicine. NCT01190306 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.